Search research articles
Contact Us
Filters
Showing results (171-180 of 174) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 174 results.
Vaccine
|
February 15, 2023
Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants
Hye Won Kwak, Hyo-Jung Park, Seo-Yeon Jung, et al.
Frontiers in Immunology
|
June 24, 2025
Discovery and development of a safe and efficient COVID-19 mRNA vaccine, STP2104, using a novel capping library screening method
Kanghyun Choi, Joo-Young Lee, Uk-Il Kim, et al.
The Lancet. Oncology
|
June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
NPJ Precision Oncology
|
March 14, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Paolo Tarantino, Se-Eun Kim, Melissa E Hughes, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 174) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 174 results.
Vaccine
|
February 15, 2023
Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants
Hye Won Kwak, Hyo-Jung Park, Seo-Yeon Jung, et al.
Frontiers in Immunology
|
June 24, 2025
Discovery and development of a safe and efficient COVID-19 mRNA vaccine, STP2104, using a novel capping library screening method
Kanghyun Choi, Joo-Young Lee, Uk-Il Kim, et al.
The Lancet. Oncology
|
June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
Mohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
NPJ Precision Oncology
|
March 14, 2026
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
Paolo Tarantino, Se-Eun Kim, Melissa E Hughes, et al.
Page
of 18